Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (8245)	1/8/1999 11:09:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

David, hu1124 is a GNE product. They sought out XOMA to take the product thru trials. GNE can do the P III itself or continue to use XOMA. Robert K thinks if hu1124 goes back in house XOMA will get 150% of expenses on hu1124 to date. I do not believe this is correct. What is clear, is that if hu1124 eventually becomes a commercial product XOMA at its' option gets a cash payment(s) or profit sharing. The term royalties was not used, so I must assume they really meant profit sharing. But since the terms of the two options were not disclosed I have no idea of what either option will mean for XOMA. Nor do we know how long P III will take regardless of who does it. I would hope that by the time P III is concluded XOMA will be in a better cash position and be freer to make the best choice, if that is profit sharing. But that is only a hope, and in reality they may be in the same or worse cash position. Excuse my style. I am not implying you don't know everything I posted. Nor that you agree with it. Rather these are my thoughts which I would want anyone to challenge. Well, almost anyone. <g>